FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:1455-1457 April 2, 2009 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Fellström, B. C. PubMed Citation

Reducing mortality from cardiovascular disease among patients undergoing dialysis is a global public health challenge. The past 10 years have seen trials of many interventions designed to improve survival and cardiovascular outcomes in these patients.^1,2,3,4 Unfortunately, none of these interventions have been shown to be effective, despite beneficial effects in surrogate markers.^5,6 It appears that statins have now joined this group of "promising but ineffective" interventions.

In this issue of the Journal, Fellström et al.⁷ report on the results of A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events . . . [Full Text of this Article]

Source Information

From the Mario Negri Sud Consortium, Santa Maria Imbaro, Italy (G.F.M.S.); the Cochrane Renal Group (G.F.M.S., J.C.C.) and the School of Public Health, University of Sydney (G.F.M.S., J.C.C.) — both in Sydney; and the Medical Scientific Office, Diaverum, Lund, Sweden (G.F.M.S.).

This article (10.1056/NEJMe0901067) was published at NEJM.org on March 30, 2009.

This article has been cited by other articles:

• (2009). Do Statins Prevent Cardiovascular Events in Hemodialysis Patients?. Journal Watch Cardiology 2009: 2-2 [Full Text]